Data Projects Legal Retail Marijuana Sales to Grow as New States Allow Use
FinancialBuzz.com News Commentary
NEW YORK, November 29, 2018 /PRNewswire/ --
Marijuana advocates scored several important ballot wins on Election Day earlier this month. The legalization of recreational marijuana in Michigan, which is now the 10th state in the U.S to approve recreational products, is one of them. In addition, Utah and Missouri legalized medical cannabis use. According to recent data published by New Frontier Data, the three new markets are projected to account for more than USD 1.2 Billion in additional sales for a combined total of USD 2.1 Billion in total legal sales by 2025. This increase will create more than 30,000 additional cannabis jobs over the same period. After the midterm elections, cannabis legalization, of some form, has occurred in about 60% of the country and based on New Frontier's research, legal retail sales revenues are currently estimated to be USD 10.3 Billion in 2018. CLS Holdings, USA Inc. (OTC: CLSH), Aphria Inc. (NYSE: APHA), Pyxus International Inc. (NYSE: PYX), MariMed Inc. (OTC: MRMD), iAnthus Capital Holdings, Inc. (OTC: ITHUF)
"Michigan will be the first state in the Midwest to end marijuana prohibition and replace it with a system in which marijuana is regulated for adult use," Marijuana Policy Project Deputy Director Matthew Schweich, who directed the legalization campaign, said in a statement according to the Washington Post. "Adults will no longer be punished for consuming a substance less harmful than alcohol, and rather than having to resort to the illegal market, they will be able to access it safely and legally from licensed businesses."
CLS Holdings, USA Inc. (OTCQB: CLSH) earlier this month announced breaking news that, "it has loaned $5 million to In Good Health, a licensed medical dispensary in Brockton, Massachusetts with a significant market share.
CLS continues with its plans and looks forward to the opportunity to enter the rapidly growing Massachusetts market, which has been operating as a legalized medical jurisdiction since 2015 and has approved legalized recreational use.
In Good Health is located 25 miles south of downtown Boston and is one of the 38 licensed dispensaries in the state. The Brockton dispensary was the second licensed dispensary in the state and has been operational since September 2015, which has been medical only up until this time. In Good Health is currently servicing 17,000 registered patients and delivering to 1,700 homes with key product offerings of flower, concentrates, vapes, edibles, pre-rolls and tinctures.
Massachusetts has a population of 6.9 million people as compared to 5.6 million people in Colorado. Massachusetts is also centrally located to the dense population of New England with a less than 100-mile drive from Rhode Island, Connecticut, New York, New Hampshire and Vermont. In 2017, Colorado generated $1.5 billion in legalized marijuana sales and had over 500 licensed dispensaries and over 700 licensed cultivation facilities. Massachusetts currently has issued only 39 licensees.
Jeff Binder, Chief Executive Officer of CLS Holdings USA, commented, 'We are pleased to have continued to move forward with In Good Health in a timely manner and are extremely excited to have the opportunity to enter the Massachusetts market. This opportunity fits into our stated objective of entering markets that have attractive characteristics and are on the cusp of implementing a robust adult use market.'"
Aphria Inc. (NYSE: APHA) is a leading global cannabis company driven by an unrelenting commitment to our people, product quality and innovation. Aphria Inc. recently announced its proposed acquisition of CC Pharma GmbH, a leading distributor of pharmaceutical products to more than 13,000 pharmacies in Germany. The transaction, when closed, will strengthen the Company's end-to-end medical cannabis operations and infrastructure in Germany, a key market in Aphria's international expansion. It is anticipated that the transaction will close in January 2019. The transaction will bolster Aphria's growing presence in Germany, which includes a three-pronged approach covering demand, supply and distribution. Earlier this year, the Company, through its wholly-owned subsidiary Aphria Deutschland, acquired a 25.1% interest in Berlin-based Schöneberg Hospital, providing access to both doctors and patients to support education about the benefits of medical cannabinoids. It was also the first step in Aphria Germany's plans to build and operate pain treatment centres throughout Germany. "This acquisition strengthens our foothold in Germany, one of the most highly sought-after medical cannabis markets in the world," said Vic Neufeld, Chief Executive Officer of Aphria. "CC Pharma is cash-flow positive and has significant experience with regulatory requirements and international logistics. It will be a strong addition to Aphria's presence in Germany, providing deeper access to the important pharmacist channel and advancing our ambitious global growth strategy."
Pyxus International Inc. (NYSE: PYX) is a global agricultural company with 145 years' experience delivering value-added products and services to businesses and customers. Pyxus International Inc. recently announced that its indirect Canadian subsidiary, Goldleaf Pharm Inc., has received its Access to Cannabis for Medical Purposes Regulations (ACMPR) cultivation license from Health Canada. The license, awarded September 28, 2018, permits Goldleaf Pharm to begin cultivating medicinal cannabis at its Simcoe, Ontario facility. Goldleaf Pharm is a subsidiary of Pyxus' indirect Canadian subsidiary, FIGR Inc. This latest milestone follows shortly after an announcement by FIGR that its Charlottetown subsidiary, Canada's Island Garden Inc. (CIG), received approval from Health Canada for the sale of medicinal cannabis oils. CIG previously announced a supply agreement with the province of Prince Edward Island for 1,000 kilograms/kilogram equivalent of cannabis products. "This is an important step, and an exciting time, for us at Goldleaf Pharm," said Larry Huszczo, Goldleaf Pharm's Co-Founder. "We have a state of the art 20,000 square foot indoor growing facility, and recently acquired 20-acres of adjacent property, giving us the ability to expand to more than 700,000 square feet of production space to cultivate cannabis. I am very proud of our team, which has worked diligently to meet Health Canada's requirements."
MariMed Inc. (OTCQB: MRMD) provides turnkey solutions to cannabis cultivators, producers, and dispensaries. MariMed Inc. recently announced that it has finalized the acquisition of BSC Group, a highly respected cannabis firm headquartered in New Jersey that over the last three years has been engaged in competitive licensing, consulting and operations management across the country. BSC founders and managing partners, Brian Staffa and Amber Staffa, will join the MariMed leadership team, bringing under the MariMed umbrella their extensive cannabis expertise, resources, intellectual property and a vast network of highly specialized affiliates spanning regulated fields of commercial cannabis, food and beverage, commercial agriculture, pharmaceuticals, regulatory compliance, consumer psychology, and the applied sciences. "Our team has worked with BSC Group on various projects in the past, and their laser focus made them an ideal partner to help fuel MariMed's forward momentum," said MariMed Chief Executive Officer Bob Fireman. "We are excited to bring on Amber and Brian, who have seasoned cannabis operations, corporate strategy, branding and marketing expertise. An organization is only as good as the people in it. The Staffas share our vision and work ethic and will be a great addition to our team."
iAnthus Capital Holdings, Inc. (OTCQX: ITHUF) owns and operates best-in-class licensed cannabis cultivation, processing and dispensary facilities throughout the United States, providing investors diversified exposure to the U.S. regulated cannabis industry. iAnthus Capital Holdings, Inc. recently announced its financial and operating results for the third quarter of 2018. All amounts expressed are in USD unless stated otherwise. The Company showed significant revenue growth during the quarter. Consolidated revenues for the Company increased 101% quarter-over-quarter, increasing to USD 1,074,398 in Q3 from USD 533,545 in Q2. System-wide revenues, including the revenues from iAnthus' investments in New Mexico and Colorado, were USD 5,139,769 in Q3, up 16% quarter-over-quarter from USD 4,415,368 in Q2. System-wide revenues from New Mexico and Colorado are unaudited and are not consolidated by the Company at present due to certain regulatory restrictions. "iAnthus continues to execute. The Company has expanded its footprint and added to its industry leading-team while maintaining a prudent balance sheet throughout the process. We are now generating revenue in five of the six markets in which we operate, with a significant number of dispensaries expected to open within the next few months. Assets are up 344% year-over-year as we grow the iAnthus platform across the United States. This performance, combined with the outlook for our Massachusetts, New York and Florida operations and the pending acquisition of MPX, position us very well for 2019."
Subscribe Now! Watch us report LIVE https://www.youtube.com/FinancialBuzzMedia
Follow us on Twitter for real time Financial News Updates: https://twitter.com/financialbuzz
Follow and talk to us on Instagram: https://www.instagram.com/financialbuzz
Facebook Like Us to receive live feeds: https://www.facebook.com/Financialbuzz/
About FinancialBuzz.com
FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.
Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.com (the 'Site') is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting high quality and sophisticated content on FinancialBuzz.com along with other financial news PR media services. FinancialBuzz.com does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along with financial and corporate news. FinancialBuzz.com only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. For CLS Holdings USA Inc. financial and corporate news dissemination, FinancialBuzz.com has been compensated five thousand dollars by the company. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. FinancialBuzz.com will always disclose any compensation in securities or cash payments for financial news PR advertising. FinancialBuzz.com does not undertake to update any of the information on the editorial or Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security. FinancialBuzz.com, members and affiliates are not responsible for any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. FinancialBuzz.com. By accessing this editorial and website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by FinancialBuzz.com constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by FinancialBuzz.com. Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use, please visit: http://www.financialbuzz.com .
Media Contact:
[email protected]
+1-877-601-1879
SOURCE FinancialBuzz.com
Share this article